Checkup Comprehensive for Men + Cancer Detection

The multi-organ detection test for men offers a high-resolution oncological evaluation. Thanks to the integration of the MBDAA algorithm and the Barcelona Criteria, its panel of 17 specific biomarkers can directly identify and characterize the cell lineage of 27 specific types of cancer. Furthermore, it indirectly alerts to the presence of virtually all solid malignant carcinomas (85-90% of all human cancers).

Unlike conventional analyses that evaluate markers in isolation, our test incorporates MBDAA (Multi-Biomarker Disease Activity Algorithm) technology. This multiparametric algorithmic intelligence model mathematically cross-references and combines the results of multiple markers synchronously.

To maximize accuracy, the MBDAA engine integrates the Barcelona Criteria, a system specifically designed to drastically reduce false positives. The algorithm is capable of detecting and identifying benign conditions that are well known in clinical practice for elevating certain tumor markers in the absence of malignancy (such as inflammatory, cystic, or metabolic dysfunction processes). By cross-referencing routine biochemistry with oncological markers under these criteria, the test filters "biological noise" from true warning signals, enabling unprecedented specificity in mapping the following processes:

The Barcelona Criteria (also known in original scientific literature as the three general rules, which formally expanded to four practical parameters) were originally established in 1994 by Dr. Rafael Molina and members of the Spanish Society of Clinical Biochemistry and Molecular Pathology (SEQCML). Their fundamental objective is to correctly interpret blood tumor markers to accurately differentiate whether an elevation is due to cancer or a benign condition, drastically reducing false positives and subsequent overdiagnosis.

This is the safety core of our test (the Barcelona Criteria at their highest expression). It is well known in clinical practice that the vast majority of tumor markers are catabolized (metabolized) in the liver and excreted (eliminated) via the kidneys. Therefore, any latent dysfunction in these organs can drastically alter blood results.

Hepatic algorithmic value: The system processes the complete panel of liver enzymes and bilirubin levels to detect benign liver diseases (such as hepatic steatosis, chronic hepatitis, or cirrhosis). If the liver is compromised and cannot properly degrade proteins, the MBDAA algorithm automatically recalibrates alerts to prevent false positives due to accumulation.

Renal algorithmic value: Concurrently, the software analyzes serum creatinine alongside urine creatinine and urine albumin to calculate eGFR and the ACR (Albumin-to-Creatinine Ratio). This allows adjusting the levels of markers with strict renal excretion (such as CYFRA 21-1, PSA, or SCC). By simultaneously monitoring the body's two essential elimination pathways (liver and kidney), the test ensures unprecedented diagnostic accuracy and safeguards the reliability of every positive result.

Specific assessment of the prostate gland through the algorithmic integration of total PSA, free PSA, and the free fraction ratio (%fPSA). This cross-analysis resolves the diagnostic gray zone (PSA levels between 4 and 10 ng/mL), differentiating with high precision between benign conditions (benign prostatic hyperplasia or prostatitis) and malignant neoplastic processes to avoid unnecessary biopsies and guide imaging studies.

Assessment of the male gonads and germ tissue through the combined and synchronous analysis of alpha-fetoprotein (AFP) and Beta-hCG (beta-human chorionic gonadotropin). This algorithmic cross-analysis enables early detection and classification of testicular germ cell tumors (seminomas and non-seminomas) as well as gonadal stromal neoplasms.

The test applies a powerful predictive algorithm combining cell-lineage-specific markers (CA 15.3, CEA, CYFRA 21-1, NSE, ProGRP, and SCC). This allows not only detecting risk, but accurately differentiating cell lineage in the analysis: squamous cell carcinoma, metastases, pulmonary small cell/neuroendocrine tumors (thanks to ProGRP and NSE), primary pulmonary adenocarcinomas (thanks to the synergistic cross-analysis of CEA and CYFRA 21-1), as well as squamous carcinomas (primarily thanks to SCC).

Trans-organ monitoring of the squamous epithelium of the upper aerodigestive tract (mouth, larynx, pharynx, and esophagus) through algorithmic cross-analysis of SCC and CYFRA 21-1, enabling early identification of squamous cell carcinomas in these regions.

Complete screening of the thyroid gland via thyroglobulin (papillary/follicular carcinomas) and calcitonin (medullary carcinoma). The algorithm enhances detection of aggressive medullary cancer by synergistically cross-referencing calcitonin with ProGRP (a neuroendocrine marker highly expressed in this tissue).

Ultra-specific evaluation of the parathyroid glands through the simultaneous analysis of intact parathyroid hormone (iPTH), serum calcium, and vitamin D (25-OH). The inclusion of vitamin D rules out secondary hyperparathyroidism (benign causes due to deficiency). Thus, the presence of elevated calcium levels coupled with autonomous secretion of iPTH activates alerts upon suspicion of hyperfunctioning adenomas or potential parathyroid carcinoma.

Comprehensive coverage of the digestive tract and its accessory glands through a sophisticated cross-analysis of oncological markers, enzymes, and pigments:

Pancreatic complex: Combines the CA 19-9 marker with the analysis of lipase, total amylase, and pancreatic amylase to detect enzymatic micro-retentions caused by compression from a latent tumor mass in the pancreas.

Biliary complex (tumor obstructive jaundice): Tracks the biliary tree by cross-referencing CA 19-9 and CEA markers with total, direct, and indirect bilirubin levels to reveal obstructive mechanics (cholangiocarcinoma).

Colorectal, gastric, and anal complex: Enhances sensitivity by cross-referencing CEA and CA 72.4 with serum iron and ferritin levels (anemias due to occult bleeding), adding the SCC marker to specifically identify squamous cell tumors of the anal canal.

Specific identification of hepatocellular carcinoma through AFP monitoring, cross-referenced under the Barcelona Criteria with liver enzyme and bilirubin profiles to mitigate false positives from benign metabolic alterations (e.g., Gilbert's syndrome or hemolysis).

Screening of the urological system by integrating urine parameters with the CYFRA 21-1 marker. By measuring soluble cytokeratin 19 fragments abundant in the urothelium, the algorithm is highly sensitive in detecting the invasive behavior of bladder cancer early.

Evaluation of the extracranial neuroectodermal system and skin tumors through the combination of protein S100 and NSE.

The routine complete blood count acts as a safety filter to identify leukocyte alterations (leukemias/lymphomas). The MBDAA algorithm jointly processes the blood count with serum iron and ferritin (a tumor acute-phase reactant) to accurately typify the origin of any anemia, rigorously applying the Barcelona Criteria.

The multi-organ detection test for men provides an in-depth mapping of male health. Through the algorithmic cross-analysis of over 100 biochemical parameters, cutting-edge Scores, and key baseline biomarkers, the test is capable of directly and indirectly evaluating, screening, and inferring over 100 diseases, pathologies, and clinical dysfunctions (reaching up to 130 variants when considering subclinical stages and metabolic syndromes). This enables early detection ranging from cardiometabolic, hormonal, and hepatic alterations to advanced renal and urological conditions.

First-line assessment. The test incorporates a series of Scores that provide a comprehensive and immediate overview of global health status. By processing metabolic, vascular, and cellular data in an integrated manner, they offer an initial synthetic framework that allows evaluating the body's homeostasis, anticipating risks of multi-organ dysfunction, and estimating resilience, biological age, and the potential for healthy longevity before delving into the details of each specific function. These Scores are:

• Cardio-Kidney-Metabolic (CKM) Score: Multi-organ predictive model that integrates the functional interaction between the vascular endothelium, renal filtration, and insulin sensitivity. This index allows staging the cardiovascular-kidney-metabolic syndrome and anticipating the risk of cross-talk multi-organ dysfunction.
• Health Score: Global metric that algorithmically weights the biological homeostasis. It serves as a synthetic indicator of systemic health by consolidating hematological, hepatic, renal, endocrine, and lipid biomarkers.
• Oxidative Stress Score: Assessment of cellular redox homeostasis. This marker allows identifying the imbalance between reactive oxygen species production and endogenous antioxidant capacity, alerting to oxidative stress states that accelerate tissue damage.
• Longevity Score: Advanced estimation of biological age and immunometabolic resilience. The algorithm is based on the PhenoAge calculation coupled with the direct integration of the Oxidative Stress Score, jointly processing low-grade chronic inflammation and redox stress to provide evidence on healthy longevity and the rate of cellular aging.

High-resolution comprehensive assessment of the hematopoietic system and bone marrow. Through the cross-analysis of the complete blood count, erythrocyte indices (MCV, MCH, and RDW), and iron dynamics (iron and ferritin), the system allows inferring and identifying the presence of micro-, normo-, or macrocytic anemias, deficiency anemias (iron deficiency or B12 deficiency), anemias associated with chronic processes, hemolytic syndromes, or latent genetic traits such as thalassemia minor.

Assessment of the innate and adaptive immune response. The differential white blood cell count breakdown acts as a biological indicator that offers clear evidence of active bacterial or viral infections, agranulocytosis, systemic allergic responses, hypereosinophilic syndromes of parasitic origin, or immunosuppressive states.

Ultra-specific study of platelets and their volumetric indices (MPV and PDW), whose findings allow for early identification of thrombocytopenia (bleeding risk), autoimmune destruction (ITP), or reactive or essential thrombocytosis.

Surveillance against systemic autoimmune and inflammatory processes. The integration of acute phase reactants (ESR and high-sensitivity C-reactive protein or hs-CRP) and autoantibodies (anti-CCP and rheumatoid factor) can support the suspicion of early development of rheumatological pathologies such as rheumatoid arthritis, systemic lupus erythematosus, or vasculitis.

Assessment of the secondary coagulation cascade. The determination of prothrombin time (PT) and activated partial thromboplastin time (aPTT) allows analyzing the extrinsic and intrinsic pathways of the cascade, guiding on the presence of congenital or acquired coagulopathies, vitamin K-dependent factor deficiencies, hepatic hemostasis impairment, or hypercoagulable states.

Comprehensive cardiometabolic risk stratification. As a starting point, the algorithm combinatorially processes the anthropometric indices—primarily analyzing body mass index (BMI), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR), alongside advanced parameters such as hypertriglyceridemic waist (HTGW), lipid accumulation product (LAP), body adiposity index (BAI), visceral adiposity index (VAI), and conicity index (CI)—with globally impactful predictive models, such as the Framingham Score, Endothelial Score, and Cardiovascular Score (CVS). This first-line multiparametric assessment allows early inference of an underlying metabolic syndrome and establishes an accurate projection of global coronary risk in the short and long term.

Advanced characterization of atherosclerotic risk and vascular health. The test tracks the atherogenic particle burden by evaluating the ApoB/ApoA1 ratio as well as 6 specific atherogenic indices: atherogenic coefficient (AC), atherogenic index of plasma (AIP), Castelli risk index I, Castelli index I integrating total bilirubin, Castelli risk index II, Castelli index II integrating total bilirubin, triglycerides/HDL-c index (THI), and the LDL-c/Lp(a) ratio. All of these are processed by an algorithm that dynamically weights each index within this family to maximize diagnostic sensitivity. This approach facilitates the detection of familial dyslipidemias or silent lipid metabolism disorders.

Specific evaluation of lipoprotein(a) [Lp(a)] as an independent genetic biomarker of cardiovascular risk. Being genetically determined and unresponsive to standard dietary interventions, elevated Lp(a) values serve as an independent indicator raising suspicion of an increased risk of early atherosclerosis, aortic stenosis, and ischemic or thrombotic events, even in individuals with normal LDL cholesterol (LDL-c) levels.

Screening for chronic vascular inflammation. Through high-sensitivity C-reactive protein (hs-CRP), the panel highlights the degree of atheromatous plaque instability, guiding on the risk of developing myocardial ischemic events.

Assessment of carbohydrate metabolism. The combination of glucose and glycated hemoglobin (HbA1c) allows anticipating the development of hypoglycemia or hyperglycemia, prediabetes, diabetes mellitus (types 1 and 2), or the risk of acute metabolic complications.

Assessment of purine metabolism. Serum urate determination points toward asymptomatic hyperuricemia states, providing an estimate of predisposition to the development of gouty arthritis (gout), tophi, or uric acid nephropathy.

Evaluation of endocrine pancreatic function and insulin dynamics. Through the analysis of basal insulin and mathematical models (HOMA-IR, HOMA-B, HOMA-S, QUICKI), the analysis allows measuring peripheral sensitivity with ultra-specificity and revealing hyperinsulinism or insulin resistance states, a key alteration in metabolic syndrome and type 2 diabetes.

Mapping of glandular function and feedback loops. The cross-analysis of TSH and free T4 allows detecting thyroid dysfunctions such as clinical (and even subclinical) hypothyroidism or hyperthyroidism.

Assessment of the parathyroid axis and calcium metabolism. The analysis of intact parathyroid hormone (iPTH), vitamin D, and phosphorus offers evidence regarding the presence of hypoparathyroidism, hyperparathyroidism, or hypercalcemia of malignancy.

Adrenal and gonadal coverage. The system allows identifying cortisol alterations (Cushing's syndrome or Addison's disease) and evaluating the testicular-pituitary axis to guide on sex steroid imbalances such as male hypogonadism, andropause (testosterone deficiency syndrome), or fertility disorders.

Assessment of hepatocellular function, biliary excretion, and liver disease screening. The enzymatic profile (ALP, AST, ALT, GGT and LDH) together with bilirubin levels (total, direct, and indirect) and alpha-fetoprotein (AFP) allow differentiating intra- or extrahepatic cholestasis processes, cholangitis, inflammatory or toxic liver diseases (hepatitis, cirrhosis), hereditary syndromes (Gilbert, Crigler-Najjar), and guiding early suspicion toward proliferative liver processes (hepatocellular carcinoma).

Non-invasive stratification of liver health. The system processes more than 15 scores and ratios through a dynamic weighting algorithm that adjusts the weights of each index to optimize diagnostic sensitivity across three key stages:

• Fat accumulation (NAFLD/MASLD): Evaluates steatosis risk using the fatty liver index (FLI), hepatic steatosis index (HSI), K-NAFLD score, liver fat score (LFS), NAFLD Logit score (NLS), and NAFLD Ridge score (NRS).
• Steatohepatitis (NASH/MASH): Determines the degree of liver inflammation by processing the acNASH model, FAT score, GHOLAM score, and HAIR score.
• Fibrosis and subclinical cirrhosis: Stages the risk of advanced tissue damage using the AST-to-platelet ratio index (APRI), BAAT score, BARD score, FibroMeter, Forns fibrosis index (FFI), NAFLD fibrosis score (NFS), and SAFE score.

Biliary tree screening. A coordinated increase in alkaline phosphatase and GGT raises suspicion of cholestasis or choledocholithiasis.

Comprehensive pancreatobiliary assessment. The joint evaluation of lipase, amylase levels (both total and pancreatic), and the tumor marker CA 19-9 allows estimating the presence and progression of acute and chronic pancreatitis, complementing the differential diagnosis of pancreatobiliary inflammatory conditions, and alerting to the suspicion of pancreatic or biliary neoplasms.

Gastrointestinal evaluation. The determination of carcinoembryonic antigen (CEA) coupled with serological screening of specific antibodies against Helicobacter pylori helps discriminate mucosal inflammatory processes, gastroduodenal ulcers, and chronic infections, providing a valuable complementary screening tool for the upper and lower digestive tract.

Striated muscle tissue integrity and lean mass assessment. Monitoring enzymes such as creatine kinase (CK) serves as an alert system to detect muscle damage, inflammatory myopathies, myotoxic side effects (such as those derived from statins), dystrophies, or rhabdomyolysis. Concurrently, muscle breakdown or loss (sarcopenia) is inferred by calculating the creatinine/cystatin C ratio, a marker that allows estimating striated muscle mass volume independently of renal function.

Bone remodeling assessment. Calcium, phosphorus, alkaline phosphatase (ALP), and vitamin D readings map out conditions such as vitamin D deficiency, osteopenia, osteoporosis, rickets, osteomalacia, or Paget's disease of bone.

Renal filtration and glomerular function. Creatinine, cystatin C, urea, blood urea nitrogen (BUN), and the urine albumin-to-creatinine ratio (ACR) allow predicting and classifying stages of acute/chronic renal failure or early microvascular damage (diabetic nephropathy, nephrotic/nephritic syndromes).

Fluid-electrolyte control and urinalysis. Urinalysis coupled with serum electrolytes can offer clear evidence of sodium, potassium, or chloride imbalances, dehydration, renal tubular acidosis, risk of nephrolithiasis, or urinary tract infections (cystitis, pyelonephritis).

Prostatic function and urological screening. The integration of total PSA, free PSA, the free fraction ratio (%fPSA), and urine markers allows distinguishing benign conditions, such as benign prostatic hyperplasia (BPH) or prostatitis, from neoplastic processes (prostate cancer). This evaluation is key to resolving the diagnostic gray zone, stratifying individualized risk, estimating glandular dynamics, and guiding the indication for imaging studies or biopsies.